The expression of TRAIL and its receptors in gastric cancer and the apoptotic effect of rh-TRAIL on SGC7901 cells

Oncology Reports

Volumn 21, Issue 3, 2009, Pages 681-688

  Hu, Jun Kun ^a   Yang, Kun ^a   Li, Chun Mei ^b   Zhang, Bo ^a   Chen, Zhi Xin ^a   Chen, Xin Zu ^a   Chen, Jia Ping ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Chemotherapeutic drugs; Gastric cancer; TNF related apoptosis inducing ligand

Indexed keywords

CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DOXORUBICIN; FAS LIGAND; FLUOROURACIL; MESSENGER RNA; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GASTRECTOMY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH CARCINOGENESIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 64849107360     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000271     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology™ Gastric Cancer V.1.2008. URL: http://www.nccn.org/ professionals/physician_gls/PDF/gastric.pdf. (accessed July 15, 2008)
3. Blank VC, Peña C and Roquin LP: A cyclic chimeric interferon-alpha2b peptide induces apoptosis in tumor cells. Cancer Biol Ther 6: 1787-1793, 2007.
4. Das T, Sa G, Hilston C, et al: GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. Cancer Res 68: 2014-2023, 2008.
5. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S and Fujiwara K: A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 19: 1060-1067, 2008.
6. Tatsumi N, Oji Y, Tsuji N, et al: Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol 32: 701-711, 2008.
7. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
8. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
9. Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997.
10. Emery JG, McDonnell P, Burke MB, et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 14363-14367, 1998.
11. Abou El Hassan MA, Mastenbroek DC, Gerritsen WR, Giaccone G and Kruyt FA: Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. Br J Cancer 91: 171-177, 2004.
12. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1: 10-24, 1998.
13. Fernandes BJ, Yao XY, Hao Y, Sutherland DJ, Sidlofsky S and Blackstein ME: DNA content and estrogen receptors in primary carcinoma of the breast. Can J Surg 34: 349-355, 1991.
14. Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ: Intracellular regulation of TRAIL-induced apoptossi in human melanoma cells. J Immunol 161: 2833-2840, 1998.
15. Pan G, O' Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113, 1997.
16. Griffith TS and Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998.
17. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
18. Sheikh MS, Huang Y, Fernandez-Salas EA, et al: The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 18: 4153-4159, 1999.
19. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620, 2000.
20. Xu SQ and El-Deiry WS: p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 269: 179-190, 2000.
21. Pan G, Ni J, Wei YF, Yu G, Gentz R and Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818, 1997.
22. Yang LQ, Fang DC, Wang RQ and Yang SM: Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 10: 22-25, 2004.
23. Hamasu T, Inanami O, Asanuma T and Kuwabara M: Enhanced induction of apoptosis by combined treatment of human carcinoma cells with X rays and death receptor agonists. J Radiat Res 46: 103-110, 2005.
24. Kanehara I, Nakata B and Hirakawa K: Caspase-8 is scarcely silenced and its activity is well correlated with the anticancer effect of tumor necrosis factor-related apoptosis-inducing ligand in gastric cancer cells. Oncol Rep 14: 1249-1253, 2005.
25. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seol DW and Lee BL: Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94: 1066-1073, 2003.
26. Kimberley FC and Screaton GR: Following a TRAIL: update on a ligand and its five receptors. Cell Res 14: 359-372, 2004.
27. Koyama S, Koike N and Adachi S: Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol 128: 73-79, 2002.
28. Nagata S and Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
29. Suda T, Takahashi T, Golstein P and Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993.
30. Martin JH, Potthoff A, Ledig S, et al: Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis. Helicobacter 9: 371-386, 2004.
31. Ashkenazi A, Holland P and Eckhardt SG: Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/ TRAIL). J Clin Oncol 26: 3621-3630, 2008.
32. Wei XC, Wang XJ, Chen K, Zhang L, Liang Y and Lin XL: Killing effect of TNF-related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87. World J Gastroenterol 7: 559-562, 2001.
33. Meurette O, Fontaine A, Rebillard A, Le Moigne G, Lamy T, Lagadic-Gossmann D and Dimanche-Boitrel MT: Cytotoxicity of TRAIL/ anticancer drug combinations in human normal cells. Ann NY Acad Sci 1090: 209-216, 2006.
34. Pan Q, Liu B, Liu J, Cai R, Wang Y and Qian C: Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem 304: 315-323, 2007.
35. Lee KC, Hamstra DA, Bhojani MS, Khan AP, Ross BD and Rehemtulla A: Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res 13: 1839-1846, 2007.
36. Shimoyama S, Mochizuki Y, Kusada O and Kaminishi M: Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. Int J Oncol 21: 643-648, 2002.
37. Shamimi-Noori S, Yeow WS, Ziauddin MF, et al: Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther 15: 356-370, 2008.
38. Ganten TM, Haas TL, Sykora J, et al: Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11: S86-S96, 2004.
39. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM and Fulda S: Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68: 6271-6280, 2008.
40. Gaiser T, Becker MR, Habel A, Reuss DE, Ehemann V, Rami A and Siegelin MD: TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin. Neurosci Lett 442: 109-113, 2008.
41. Arts HJ, de Jong S, Hollema H, ten Hoor K, van der Zee AG and de Vries EG: Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol 92: 794-800, 2004.
42. Shankar S, Chen X and Srivastava RK: Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62: 165-186, 2005.
43. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA and Bonavida B: Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 6: 1387-1399, 2007.
44. Dong HP, Kleinberg L, Silins I, et al: Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer 112: 84-93, 2008.